{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Summit+Therapeutics", "query": { "sponsor": "Summit Therapeutics" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Summit+Therapeutics&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-04T10:36:46.407Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07815665", "title": "A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Metastatic Urothelial Carcinoma (UC)" ], "interventions": [ { "name": "Ivonescimab Dose 1", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Ivonescimab Dose 2", "type": "DRUG" }, { "name": "Ivonescimab RP3D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2026-09-10", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07815665" }, { "nct_id": "NCT04802837", "title": "Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridioides Difficile Infection" ], "interventions": [ { "name": "Ridinilazole", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 2, "start_date": "2021-05-19", "completion_date": "2022-09-28", "has_results": true, "last_update_posted_date": "2023-08-21", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 18, "location_summary": "Los Angeles, California • Orange, California • Miami, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04802837" }, { "nct_id": "NCT05899608", "title": "Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Ivonescimab Injection", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab Injection", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1600, "start_date": "2023-10-26", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 76, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 61 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05899608" }, { "nct_id": "NCT02092935", "title": "A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Infection" ], "interventions": [ { "name": "SMT19969", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 100, "start_date": "2014-04", "completion_date": "2015-10", "has_results": false, "last_update_posted_date": "2016-10-20", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 24, "location_summary": "Mobile, Alabama • Laguna Hills, California • Long Beach, California + 21 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Laguna Hills", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "Ventura", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02092935" }, { "nct_id": "NCT06396065", "title": "Phase III Study of AK112 for NSCLC Patients", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-small Cell Lung Cancer" ], "interventions": [ { "name": "AK112 Injection", "type": "DRUG" }, { "name": "Placebo Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 420, "start_date": "2023-05-04", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 43, "location_summary": "Bakersfield, California • La Jolla, California • Los Angeles, California + 35 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06396065" }, { "nct_id": "NCT07743138", "title": "STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adrenocortical Carcinoma", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "Ivonescimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2027-02-07", "completion_date": "2030-05-01", "has_results": false, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07743138" }, { "nct_id": "NCT07397338", "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Solid Tumors", "Non-small Cell Lung Cancer (NSCLC)", "NSCLC", "Colorectal Cancer (CRC)", "CRC" ], "interventions": [ { "name": "Daraxonrasib", "type": "DRUG" }, { "name": "Elironrasib", "type": "DRUG" }, { "name": "Zoldonrasib", "type": "DRUG" }, { "name": "Ivonescimab", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Dose Expansion Only)", "type": "DRUG" }, { "name": "cetuximab (Cohort C2 Only)", "type": "DRUG" }, { "name": "Carboplatin/Cisplatin + Pemetrexed (Cohort B2 Only)", "type": "DRUG" }, { "name": "Daraxonrasib (Cohort B1 only)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Revolution Medicines, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 370, "start_date": "2026-01-30", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-08-03", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 8, "location_summary": "Los Angeles, California • Norwich, Connecticut • Saint Paul, Minnesota + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Saint Paul", "state": "Minnesota" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07397338" }, { "nct_id": "NCT03595553", "title": "Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Clostridioides Difficile Infection" ], "interventions": [ { "name": "Ridinilazole", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 759, "start_date": "2019-01-28", "completion_date": "2021-11-17", "has_results": true, "last_update_posted_date": "2023-03-03", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 49, "location_summary": "Birmingham, Alabama • Sun City, Arizona • Los Angeles, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Redding", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03595553" }, { "nct_id": "NCT06672575", "title": "A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Ivonescimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2025-01-30", "completion_date": "2030-01-31", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06672575" }, { "nct_id": "NCT06805617", "title": "A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Salivary Gland Cancer", "Advanced Salivary Gland Carcinoma", "Metastatic Salivary Gland Cancer", "Adenoid Cystic Carcinoma" ], "interventions": [ { "name": "Ivonescimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Glenn J. Hanna", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2025-02-26", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-04T10:36:46.407Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06805617" } ] }